Thymulin
Also referenced as: Zinc-thymulin
A zinc-dependent thymic nonapeptide complex studied in immune and hair biology.
- Evidence grade
- EExperimental / Limited Evidence
Experimental / Limited Evidence
- Regulatory status
- Investigational
Investigational; not FDA-approved for the uses discussed.
- Human data
- Limited
No registered clinical trials identified
- Last reviewed
- October 27, 2026
Overview
A zinc-dependent thymic nonapeptide complex studied in immune and hair biology.
Investigational; not FDA-approved for the uses discussed.
An uncontrolled topical report cannot establish efficacy or validate injected thymulin.
Why It's Being Studied
- Thymic signalling
- Exploratory hair research
Mechanism of Action
It is associated with T-cell differentiation and immune regulation, but is distinct from thymosin alpha-1.
It is associated with T-cell differentiation and immune regulation, but is distinct from thymosin alpha-1. An uncontrolled topical report cannot establish efficacy or validate injected thymulin.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Thymic signalling
- Exploratory hair research
- Topical exploratory research
- Cell and animal research
Evidence Summary
A small uncontrolled topical alopecia report is exploratory, not confirmation of hair growth or systemic immune benefit.
Higher tiers carry more weight. Filled tiers have evidence for Thymulin; tap to read it.
- A small uncontrolled topical alopecia report is exploratory, not confirmation of hair growth or systemic immune benefit.
1 cited sources.
- Observational study1
Observational evidence
- A small uncontrolled topical alopecia report is exploratory, not confirmation of hair growth or systemic immune benefit.
Reported Adverse Events in Research
- Long-term and systemic safety are inadequately characterized; lack of controlled replication prevents reliable risk-benefit estimates.
Limitations of Current Evidence
- An uncontrolled topical report cannot establish efficacy or validate injected thymulin.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Thymulin | Trofinetide | |
|---|---|---|
| Evidence grade | E — Experimental / Limited Evidence | B — Moderate Human Evidence |
| Regulatory status | Investigational | FDA Approved for Specific Indication |
| Human data | Limited | Yes |
| Clinical trials | None identified | Registered trials exist |
| Research routes | Topical exploratory research, Cell and animal research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Observational study
Thymulin — observational study